Treatment Considerations in First Line Setting of Metastatic Castration-Resistant Prostate Cancer

Safety and Disease Related Outcomes of mCRPC Patients Who Were Treated with Radium-223 Then 177Lu-PSMA (RALU) - Neal Shore

March 5, 2023

Details

The Association Between the Time Interval Between Sequential Treatment With Radium-223 Therapy and 177Lu-PSMA in the RALU Study - Kambiz Rahbar

March 3, 2023

Details

Sequencing Radiopharmaceuticals: Efficacy and Safety Data of Radium-223 Followed by Lutetium-177-PSMA in the RALU Study - Oliver Sartor

January 31, 2023

Details

Radiopharmaceuticals in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer – A Cased Based Review - Phillip Koo, Neal Shore, & Alicia Morgans

January 31, 2023

Details

Optimal Treatment Sequencing with Radiopharmaceuticals After Radium-223 in Men with Newly Progressed Prostate Cancer – A Cased Based Review - Phillip Koo, Neal Shore, & Alicia Morgans

January 26, 2023

Details

Sequencing of Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer - Pedro Barata

January 26, 2023

Details

223Ra Use Before 177Lu-PSMA for Patients with Bone-predominant mCRPC, The RAdium LUtetium (RALU) Study, Journal Club - Zachary Klaassen

November 30, 2022

Details